OasisLMS

As a direct result of the evolving technologies and procedures related to the surgical management of BPH, urologists must continue increasing their knowledge and skills of the various treatment options available.

• Olympus Corporation of the Americas
• Teleflex Interventional Urology

• Urologists
• Residents
• Advanced Practice Providers

After participating in this educational series, participants will be able to:

1. Utilize the newly released AUA Guidelines Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice.
2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.
3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.
4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.

FACULTY DISCLOSURES

Faculty disclosures will be posted here prior to the start of the course.

EDUCATION COUNCIL DISCLOSURE

Education Council DTL 2025.pdf

COI REVIEW WORK GROUP DISCLOSURES

COI Review Workgroup DTL 2025.pdf

AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.

1) Pre-Test Activity

2) Welcome & Introductions

1. Interview-Style Discussion with Course Director/Faculty
2. i) Explores the who, what, and why of AUA’s BPH Guideline and how it will affect clinical practice.
3. ii) Provides first hand, clinical accounts that illustrate the proper application and role of these guidelines in day-to-day practice.
4. iii) Demonstrates the importance of communicating proper patient expectations regarding treatment of BPH and maintaining a patient-centered focus.
5. iv) Review of pivotal studies for minimally invasive treatments of BPH.

4) Discussion and Review Surgical Techniques

a) Explanation of procedures, differentiate between each of the new technologies (mode of action/quality of supporting evidence)

5) Question & Answer and Post-Test

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

Live Webinar: The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credits^TM.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.